Premier Alternatives

Accipiter Biosciences

Seattle, WA · Founded 2023 · Privately Held (backing)

Developer of a biotechnology platform designed to engineer de novo biologics for the treatment of complex diseases. Accipiter Biosciences is based in Seattle, WA and was founded in 2023. It was valued at $22 million at its seed round in Nov 2025, the last priced event on record. It has raised $13.6 million across 2 recorded rounds; the latest was a $13.6 million early-stage round in May 2024.

PMV mark · valuation
$22.0M
Oct 2026
Priced at
its seed round
Nov 2025
Total raised
$13.6M
Last round
Early Stage VC
May 2024

Accipiter Biosciences key facts

as of Oct 2026
  • Developer of a biotechnology platform designed to engineer de novo biologics for the treatment of complex diseases.
  • Accipiter Biosciences is valued at approximately $22.0M as of Oct 2026, set at its seed round, Nov 2025; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $13.6M across 2 recorded rounds; the latest was Early Stage VC ($13.6M) in May 2024.
  • Notable investors include Creative Destruction Lab, Alexandria Venture Investments, Cercano Management, Argonautic Ventures, WRF Capital — 9 tracked in total.
  • Accipiter Biosciences has filed 3 Form Ds with the SEC since 2023, most recently Sep 2025 ($13.6M sold to 15 investors).
  • Status: Privately Held (backing).
PrivateMarketView mark
MEDIUM confidence
$22.0M

Valued at $22.0M at its seed round, Nov 2025. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of Accipiter Biosciences with a free account
  • ·Watch Accipiter Biosciences: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Accipiter Biosciences funding rounds

2 rounds
May 2024Early Stage VC$13.6MSEC filing▮
Apr 2023Seed Round$650KSEC filing▮
Full funding history →

Accipiter Biosciences valuation

Accipiter Biosciences was valued at $22 million at its seed round in Nov 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Accipiter Biosciences raised?

Accipiter Biosciences has raised $13.6 million across 2 recorded rounds since 2023. The largest was a $650,000 seed round in Apr 2023; the most recent was a $13.6 million early-stage round in May 2024.

Accipiter Biosciences has filed 3 Form Ds with the SEC since 2023, most recently in Sep 2025 ($13.6 million sold to 15 investors).

Accipiter Biosciences investors

9 investors are on record for Accipiter Biosciences, including Creative Destruction Lab, Alexandria Venture Investments, Cercano Management and Argonautic Ventures. The early-stage round in May 2024 drew 15 investors.

About Accipiter Biosciences

Developer of a biotechnology platform designed to engineer de novo biologics for the treatment of complex diseases. The company offers computationally designed multifunctional proteins that combine multiple mechanisms within a single molecule, enabling biopharmaceutical companies and healthcare providers to develop therapies with improved safety, effectiveness, and patient convenience.

Sector
Healthcare
HQ
Seattle, WA, United States
Founded
2023
Employees
18
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.